Telix Pharmaceuticals (TLX) Receivables Refunds (2023 - 2025)
Telix Pharmaceuticals has reported Receivables Refunds over the past 3 years, most recently at $6.0 million for Q4 2025.
- Quarterly Receivables Refunds fell 2.87% to $6.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.0 million through Dec 2025, down 2.87% year-over-year, with the annual reading at $6.0 million for FY2025, 2.22% up from the prior year.
- Receivables Refunds was $6.0 million for Q4 2025 at Telix Pharmaceuticals, down from $6.2 million in the prior quarter.
- Over five years, Receivables Refunds peaked at $6.2 million in Q4 2024 and troughed at $3.1 million in Q4 2023.
- The 3-year median for Receivables Refunds is $6.0 million (2025), against an average of $5.1 million.
- Year-over-year, Receivables Refunds surged 101.67% in 2024 and then dropped 2.87% in 2025.
- A 3-year view of Receivables Refunds shows it stood at $3.1 million in 2023, then surged by 101.67% to $6.2 million in 2024, then fell by 2.87% to $6.0 million in 2025.
- Per Business Quant, the three most recent readings for TLX's Receivables Refunds are $6.0 million (Q4 2025), $6.2 million (Q4 2024), and $3.1 million (Q4 2023).